Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 717.21M | 670.21M | 673.21M | 630.58M | 610.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 717.21M | 670.21M | 673.21M | 630.58M | 610.14M |
| Cost of Revenue | 866.83M | 853.83M | 859.83M | 832.27M | 779.20M |
| Gross Profit | -149.62M | -183.62M | -186.62M | -201.69M | -169.06M |
| SG&A Expenses | 348.56M | 347.56M | 348.56M | 342.51M | 336.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.22B | 1.20B | 1.21B | 1.17B | 1.12B |
| Operating Income | -498.17M | -531.17M | -535.17M | -544.20M | -505.29M |
| Income Before Tax | -582.23M | -605.23M | -571.23M | -576.36M | -530.03M |
| Income Tax Expenses | 3.74M | 3.74M | 3.74M | 3.26M | 2.69M |
| Earnings from Continuing Operations | -585.97 | -608.97 | -574.97 | -579.62 | -532.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -585.97M | -608.97M | -574.97M | -579.62M | -532.72M |
| EBIT | -498.17M | -531.17M | -535.17M | -544.20M | -505.29M |
| EBITDA | -464.78M | -496.78M | -499.78M | -508.05M | -469.00M |
| EPS Basic | -5.84 | -6.10 | -5.83 | -5.94 | -5.53 |
| Normalized Basic EPS | -3.44 | -3.60 | -3.62 | -3.69 | -3.44 |
| EPS Diluted | -5.84 | -6.10 | -5.83 | -5.94 | -5.53 |
| Normalized Diluted EPS | -3.44 | -3.60 | -3.62 | -3.69 | -3.44 |
| Average Basic Shares Outstanding | 402.17M | 398.77M | 394.47M | 390.25M | 385.98M |
| Average Diluted Shares Outstanding | 402.17M | 398.77M | 394.47M | 390.25M | 385.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |